SGMT Sagimet Biosciences Inc. - Seri
$10.42▲ +9.00%
Healthcare
Other
After hours
$10.42▲ +0.00%
Oct 27, 4:01 PM ET
Volume 1.11M
Avg Volume (10D) 1.47M
Key Metrics & Fundamentals
Market Cap
$738.87M
P/E Ratio
–
Div Yield
0.00%
52W Range
4.50 - 11.45
% vs 50 MA
4.85%
% vs 200 MA
40.14%
RSI-14
60.0
MACD Histogram
+0.2200
Beta (1Y vs SPY)
1.97
Free Cash Flow
-$11.10M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$15.82M
COGS
–
Operating Exp
$15.82M
Operating Income
-$15.82M
EBIT
-$15.82M
Pretax Income
-$13.95M
Net Income
-$13.95M
EPS (Diluted)
-0.26
Price & Volume History
Loading chart…
Recent News
Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet
Zacks · Oct 23, 2026 8:55 AM ET
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
PR Newswire · Oct 22, 2026 8:10 PM ET
Sagimet Biosciences Doses First Patient in US Phase 3 Trial of Denifanstat to Treat Acne
MT Newswires · Oct 22, 2026 9:30 AM ET
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
GlobeNewswire · Oct 22, 2026 7:00 AM ET
After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
Zacks · Oct 15, 2026 8:35 AM ET
Sagimet Says Denifanstat Shows Continued Improvement in Acne Through 52 Weeks in China Trial
MT Newswires · Oct 9, 2026 8:18 AM ET
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
GlobeNewswire · Oct 9, 2026 7:00 AM ET
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
MarketBeat · Oct 3, 2026 9:02 PM ET
Sagimet Biosciences Closes Offering of Shares, Warrants
MT Newswires · Oct 1, 2026 5:30 PM ET
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
GlobeNewswire · Oct 1, 2026 4:31 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SGMT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.